B. Braun Medical Inc. (B. Braun), a market leader in renal therapies, infusion therapy, and pain management, has signed an agreement to acquire the bloodlines business operated under the Medisystems® name by NxStage Medical, Inc., a medical technology company based in Lawrence, Massachusetts (NxStage). The bloodlines business includes blood tubing solutions designed to eliminate blood air interface and a tubing product that eases the reversal of blood flow during treatment.
NxStage Medical, Inc. develops, manufactures and markets innovative products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. NxStage also has established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD.
We are pleased to add the Streamline®bloodline to our dialysis product portfolio. Although we have been selling Streamline for many years, this acquisition will allow us to more broadly promote Streamline’s benefits as part of our transformative system of products, which includes the Dialog® hemodialysis machine and the Diacap® PRO dialyzer,” said Sam Amory, Vice President of B. Braun Medical.
Financial details of the acquisition were not disclosed. The acquisition is subject to Federal Trade Commission approval and contingent upon the closing of the pending $2B merger of NxStage with a subsidiary of Fresenius Medical Holdings, Inc.